Letter to Editor
BibTex RIS Cite

Tildrakizumab for the treatment of exfoliative cheilitis

Year 2023, Volume: 6 Issue: 1, 19 - 21, 31.01.2023
https://doi.org/10.33204/mucosa.1209480

Abstract

Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.

References

  • Cai L, Wei J, Ma D, et al. Predisposition of hypersensitivity in patients with exfoliative cheilitis. J Dent Sci 2022;17:476-81.
  • Georgakopoulou E, Loumou P, Grigoraki A, Panagiotopoulos A. Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%. Med Oral Patol Oral Cir Bucal 2021;26:e357-e60.
  • Liu J, Shi L, Wang X, et al. Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: A randomised controlled clinical trial and monitoring blood concentration. J Oral Pathol Med 2021;50:251-9.
  • Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005;141:1080-2.
  • Gueutier A, Leducq S, Joly A, Picon L, Vaillant L, Samimi M. Efficacy of vedolizumab in granulomatous cheilitis refractory to TNFα inhibitors. Int J Dermatol 2019;58:e236-e7.
  • Taxonera C, Alba C, Colmenares M, Olivares D, Rey E. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review. Therap Adv Gastroenterol 2020;27:13.

Eksfolyatif keilit tedavisinde tildrakizumab

Year 2023, Volume: 6 Issue: 1, 19 - 21, 31.01.2023
https://doi.org/10.33204/mucosa.1209480

Abstract

References

  • Cai L, Wei J, Ma D, et al. Predisposition of hypersensitivity in patients with exfoliative cheilitis. J Dent Sci 2022;17:476-81.
  • Georgakopoulou E, Loumou P, Grigoraki A, Panagiotopoulos A. Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%. Med Oral Patol Oral Cir Bucal 2021;26:e357-e60.
  • Liu J, Shi L, Wang X, et al. Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: A randomised controlled clinical trial and monitoring blood concentration. J Oral Pathol Med 2021;50:251-9.
  • Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005;141:1080-2.
  • Gueutier A, Leducq S, Joly A, Picon L, Vaillant L, Samimi M. Efficacy of vedolizumab in granulomatous cheilitis refractory to TNFα inhibitors. Int J Dermatol 2019;58:e236-e7.
  • Taxonera C, Alba C, Colmenares M, Olivares D, Rey E. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review. Therap Adv Gastroenterol 2020;27:13.
There are 6 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Letter to Editor
Authors

Timothy Cowan 0000-0003-1212-269X

Nada Abu Alrub 0000-0003-3082-2876

Anna Wilson 0000-0001-5596-2109

Mani Makhija 0000-0001-6200-0055

Dedee Murrell 0000-0003-2971-0199

Publication Date January 31, 2023
Published in Issue Year 2023 Volume: 6 Issue: 1

Cite

Vancouver Cowan T, Abu Alrub N, Wilson A, Makhija M, Murrell D. Tildrakizumab for the treatment of exfoliative cheilitis. Mucosa. 2023;6(1):19-21.